Dataset Information

VMAT Optimization and Dose Calculation in the Presence of Metallic Hip Prostheses.

ABSTRACT: INTRODUCTION:This research quantifies and compares the effect of hip prostheses on dose distributions calculated using collapsed cone convolution superposition and Monte Carlo (with and without correcting for the density of the implant and surrounding tissues). The use of full volumetric modulated arc therapy arcs versus volumetric modulated arc therapy arcs avoiding the hip implants (skip arcs) was also studied. MATERIALS AND METHODS:Six prostate patients with hip prostheses were included in this study. The hip prostheses and the streaking artifacts on the computed tomography images were contoured by a single physician, and full volumetric modulated arc therapy arcs were created in the Pinnacle3 TPS. Copies of each plan were made, and the doses were recalculated with the densities of the prostheses and surrounding tissues overridden. The plans were then exported to Monaco and recalculated using a Monte Carlo dose calculation algorithm, with and without densities of the prosthesis and surrounding tissues overridden. RESULTS:With density overrides, Pinnacle3 had a 4.4% error for ion chamber measurements. Monaco was within 0.2% of ion chamber measurement when density overrides were used. On average, when density overrides were used in Pinnacle3 for patient dose calculations, the planning target volume D95 value dropped from 99.3% to 82.7%. Monaco also showed decreased planning target volume coverage when plans were recalculated with correct density information. Full arc plans (with density overrides) for the patient with a bilateral prosthesis provided significant bladder sparing and some rectal sparing compared to skip arc plans. CONCLUSION:When planning for prostate patients with hip prostheses, correct density information for implants and surrounding tissues should be used to optimize the plan and ensure optimal accuracy. If available, a Monte Carlo algorithm should be used as a second check. Full arcs could be used to spare dose to organs at risk, while maintaining adequate planning target volume coverage, when using a Monte Carlo dose calculation algorithm.

SUBMITTER: Parenica HM

PROVIDER: S-EPMC6887823 | biostudies-literature | 2019 Jan-Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

VMAT Optimization and Dose Calculation in the Presence of Metallic Hip Prostheses.

Parenica Holly M HM Mavroidis Panayiotis P Jones William W Swanson Gregory G Papanikolaou Niko N Stathakis Sotirios S

Technology in cancer research & treatment 20190101

<h4>Introduction</h4>This research quantifies and compares the effect of hip prostheses on dose distributions calculated using collapsed cone convolution superposition and Monte Carlo (with and without correcting for the density of the implant and surrounding tissues). The use of full volumetric modulated arc therapy arcs versus volumetric modulated arc therapy arcs avoiding the hip implants (skip arcs) was also studied.<h4>Materials and methods</h4>Six prostate patients with hip prostheses were ...[more]

PMID: 31789113

Similar Datasets

Project description:PurposePatient-specific quality assurance (QA) is very important in radiotherapy, especially for patients with highly conformed treatment plans like VMAT plans. Traditional QA protocols for these plans are time-consuming reducing considerably the time available for patient treatments. In this work, a new MC-based secondary dose check software (SciMoCa) is evaluated and benchmarked against well-established TPS (Monaco and Pinnacle3 ) by means of treatment plans and dose measurements.MethodsFifty VMAT plans have been computed using same calculation parameters with SciMoCa and the two primary TPSs. Plans were validated with measurements performed with a 3D diode detector (ArcCHECK) by translating patient plans to phantom geometry. Calculation accuracy was assessed by measuring point dose differences and gamma passing rates (GPR) from a 3D gamma analysis with 3%-2 mm criteria. Comparison between SciMoCa and primary TPS calculations was made using the same estimators and using both patient and phantom geometry plans.ResultsTPS and SciMoCa calculations were found to be in very good agreement with validation measurements with average point dose differences of 0.7 ± 1.7% and -0.2 ± 1.6% for SciMoCa and two TPSs, respectively. Comparison between SciMoCa calculations and the two primary TPS plans did not show any statistically significant difference with average point dose differences compatible with zero within error for both patient and phantom geometry plans and GPR (98.0 ± 3.0% and 99.0 ± 3.0% respectively) well in excess of the typical 95% clinical tolerance threshold.ConclusionThis work presents results obtained with a significantly larger sample than other similar analyses and, to the authors' knowledge, compares SciMoCa with a MC-based TPS for the first time. Results show that a MC-based secondary patient-specific QA is a clinically viable, reliable, and promising technique, that potentially allows significant time saving that can be used for patient treatment and a per-plan basis QA that effectively complements traditional commissioning and calibration protocols.

Project description:Existing volumetric modulated arc therapy (VMAT) optimization using coplanar arcs is highly efficient but usually dosimetrically inferior to intensity modulated radiation therapy (IMRT) with optimized non-coplanar beams. To achieve both dosimetric quality and delivery efficiency, we proposed in this study, a novel integrated optimization method for non-coplanar VMAT (4?VMAT). 4?VMAT with direct aperture optimization (DAO) was achieved by utilizing a least square dose fidelity objective, along with an anisotropic total variation term for regularizing the fluence smoothness, a single segment term for imposing simple apertures, and a group sparsity term for selecting beam angles. Continuous gantry/couch angle trajectories were selected using the Dijkstra's algorithm, where the edge and node costs were determined based on the maximal gantry rotation speed and the estimated fluence map at the current iteration, respectively. The couch-gantry-patient collision space was calculated based on actual machine geometry and a human subject 3D surface. Beams leading to collision are excluded from the DAO and beam trajectory selection (BTS). An alternating optimization strategy was implemented to solve the integrated DAO and BTS problem. The feasibility of 4?VMAT using one full-arc or two full-arcs was tested on nine patients with brain, lung, or prostate cancer. The plan was compared against a coplanar VMAT (2?VMAT) plan using one additional arc and collimator rotation. Compared to 2?VMAT, 4?VMAT reduced the average maximum and mean organs-at-risk dose by 9.63% and 3.08% of the prescription dose with the same target coverage. R50 was reduced by 23.0%. Maximum doses to the dose limiting organs, such as the brainstem, the major vessels, and the proximal bronchus, were reduced by 8.1 Gy (64.8%), 16.3 Gy (41.5%), and 19.83 Gy (55.5%), respectively. The novel 4?VMAT approach affords efficient delivery of non-coplanar arc trajectories that lead to dosimetric improvements compared with coplanar VMAT using more arcs.

Project description:BackgroundMetal-on-Metal (MoM) total hip arthroplasties (THA) are associated with pseudotumor formation and high revision rates. This prospective study analysed the clinical and wear analyses of 9 large Metal-on-Metal (MoM) total hip arthroplasties (THA) to understand the underlying mechanisms of failure. The MoM bearings were revised for multiple reasons; the main reason was pseudotumor formation.Materials and methodsFrom 2006 till 2010 the Reinier de Graaf Hospital implanted 160 large head M2a-Magnum™ (Biomet Inc. Warsaw, Indiana, USA) THAs in 150 patients. The first year, 9 bearings were revised and analysed at the Biomechanics Section, Hamburg University of Technology, Germany. We performed clinical (Harris Hip Score, radiographic analysis, blood cobalt and chromium) and wear analysis (implant, tissue and fluid) of the 9 bearings. Since this study did not fall under the scope of the Medical Research Involving Human Subjects Act in The Netherlands, no ethical approval was necessary. In this prospective study all patient details were anonymized by the corresponding author, all other authors were blinded during the research and wear analyses. Patients with bilateral MoM implants were excluded.ResultsThe 9 bearings had a median (IQR) survival of 41.0 (25) months in situ. From these bearings, three showed no noticeable wear. The median (IQR) head wear volume was 3.2 (3.6) mm3 and maximum wear depth 0.02 (0.02) mm. For the cup the median (IQR) wear volume was 0.23 (0.3) mm3 with a maximum wear depth of 0.03 (0.05) mm.ConclusionAn early identification of parameters related to failure of the MoM THA, such as pain, decreased range of motion, radiographic changes and high levels of blood cobalt and chromium is of great importance for patient's quality of life. Especially now patients and surgeons face the long term effects of all these bearings still in situ. This study reports the clinical and wear analyses of 9 MoM THA. In the majority of this group the reason for revision was pseudotumor formation. Most bearings showed signs of wear, however with a great diversity in clinical analysis, in inclination angle, serum cobalt and chromium levels as well as wear analysis. For a better understanding of the underlying mechanisms related with failure, more wear analyses of revised MoM bearings are necessary as well as a frequent follow-up of the patients with a MoM bearing.

Project description:The purpose of this study was to evaluate the dose differences introduced by the TMR 10 and the convolution dose calculation algorithms in GammaPlan version 10, as compared to the TMR classic algorithm in the previous versions of GammaPlan. Computed axial tomographic images of a polystyrene phantom and a human head were acquired using a GE LightSpeed VCT scanner. A treatment target with a prescription dose of 20 Gy to 50% isodose line was defined in the phantom or the head CT set. The treatment times for single collimator, single shot placements were calculated using the three dose calculation algorithms in GammaPlan version 10. Four comparative studies were conducted: i) the dose matrix position was varied every 10 mm along the x-, y-, z-axes of the stereotactic coordinate system inside the phantom and the treatment times were compared on each matrix for the three collimators of the Gamma Knife Perfexion and the four collimators of the 4C;ii) the study was repeated for the human head CT dataset; iii) the matrix position was varied every 20 mm in the X and the Y directions on the central slice (Z = 100mm) of the head CT and the shot times were compared on each matrix for the 8 mm collimator of both units; a total of 51 matrix positions were identified for each unit; iv) the above comparison was repeated for the head CT transverse slices with Z = 20, 40, 60, 80, 120, 140, and 160 mm. A total of 271 matrix positions were studied. Based on the comparison of the treatment times needed to deliver 20 Gy at 50% isodose line, the equivalent TMR classic dose of the TMR 10 algorithm is roughly a constant for each collimator of the 4C unit and is 97.5%, 98.5%, 98%, and 100% of the TMR 10 dose for the 18 mm, 14 mm, 8 mm, and the 4 mm collimators, respectively. The numbers for the three collimators of the Perfexion change with the shot positions in the range from 99% to 102% for both the phantom and the head CT. The minimum, maximum, and the mean values of the equivalent TMR classic doses of the convolution algorithm on the 271 voxels of the head CT are 99.5%, 111.5%, 106.5% of the convolution dose for the Perfexion, and 99%, 109%, 104.5% for the 4C unit. We identified a maximum decrease in delivered dose of 11.5% for treatment in the superior frontal/parietal vertex region of the head CT for older calculations lacking inhomogeneity correction to account for the greater percentage of the average beam path occupied by bone. The differences in the inferior temporal lobe and the cerebellum/neck regions are significantly less, owing to the counter-balancing effects of both bone and the air cavity inhomogeneities. The dose differences between the TMR 10 and the TMR classic are within ± 2.5% for a single shot placement on both Perfexion and 4C. Dose prescriptions based on the experiences with the TMR classic may need to be adjusted to accommodate the up to 11.5% difference between the convolution and the TMR classic.

Dataset Information

VMAT Optimization and Dose Calculation in the Presence of Metallic Hip Prostheses.

Publications

VMAT Optimization and Dose Calculation in the Presence of Metallic Hip Prostheses.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets